Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
22 Abril 2021 - 9:00AM
Nearly 19 million more American adults – about a third of those now
refusing to get vaccinated – would get vaccinated if they could
take a pill instead of getting a shot, according to a poll
conducted by Quadrant Strategies and commissioned by Vaxart, Inc.
The survey found that 23% of respondents said they do not plan
to get vaccinated but nearly a third of them said they would if the
vaccine were available as a pill instead of by a needle
injection.
The results suggest that about half of the additional vaccinated
group would be drawn from minority populations, communities that
have disproportionately not been vaccinated. The Centers for
Disease Control and Prevention report only 12% of Hispanics,
9% of Blacks, and 6% of Asians have received vaccines as of April
21, 2021.
“Vaccinating another 19 million American adults may help the US
reach herd immunity. The public health and societal implications of
an oral Covid-19 vaccine could be both broad and profound,” said
Vaxart chief executive officer Andrei Floroiu.
“This poll suggests as many as an additional 4 million Black, 3
million rural, 2 million Hispanic and 1 and a half million Asian
Americans would take a pill Covid-19 vaccine. That provides an
important path to reducing healthcare inequity in this country and
to alleviating the disproportionate impact Covid-19 has had on
predominantly minority and rural communities,” Floroiu said.
“It is not surprising that seven in 10 Americans prefer a pill
to getting stuck with a needle,” Vaxart chief science officer Sean
Tucker said. “Needle injections present a barrier to getting people
vaccinated and we have a solution that we believe will be effective
and would allow people to avoid injections they don’t want to
have.”
Nearly a quarter of respondents said they are afraid of needles
and that fear is found among all groups.
“We need to tear down this barrier to vaccinating more
Americans. A pill option taken at home on their own time raises the
number of Americans likely to get a Covid-19 vaccine in a material
way,” Floroiu said.
The national survey of 1,500 Americans over the age of 18,
conducted by Quadrant Strategies between March 17 and 24, also
found that:
- 7 in 10 said they’d prefer taking a
vaccine pill rather than getting injected with a vaccine.
- 7 in 10 said they’d prefer taking a
pill at home rather than going somewhere to get vaccinated.
- 8 in 10 support speeding up the
development of new vaccines that can respond more quickly to new
virus strains as they appear. An overwhelming majority are worried
that current vaccine development can’t keep up with the new
strains.
This survey’s findings come as the government has reported newer
and more variants of Covid-19 in the United States.
Vaxart recently completed the Phase 1 study of its oral tablet
coronavirus vaccine:
- The study reached primary and
secondary endpoints of safety and immunogenicity,
respectively.
- VXA-CoV2-1 induced potent
CD8+ T-cell responses that are potentially protective against
the original as well as new and emerging Covid-19 strains.
Survey Methodology
Quadrant Strategies conducted an online national survey of 1,500
Americans 18 and older between March 17 and 24, 2021. The margin of
error is +/- 3%. Quadrant Strategies is based in Washington,
D.C.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing
a range of oral recombinant vaccines based on its proprietary
delivery platform. Vaxart vaccines are designed to be
administered using tablets that can be stored and shipped without
refrigeration and eliminate the risk of needle-stick
injury. Vaxart believes that its proprietary tablet
vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Its development programs currently include tablet
vaccines designed to protect against coronavirus, Norovirus,
seasonal influenza and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immuno-oncology indication. Vaxart has filed broad
domestic and international patents covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding Vaxart’s strategy, prospects, plans and objectives,
results from pre-clinical and clinical trials, commercialization
agreements and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “should,” “believe,” “could,”
“potential,” “will,” “expected,” “plan” and other words and terms
of similar meaning. Examples of such statements include, but are
not limited to, statements relating to Vaxart’s ability to develop
and commercialize its product candidates and clinical results and
trial data; Vaxart’s expectations with respect to the important
advantages it believes its oral vaccine platform can offer over
injectable alternatives for SARS-CoV-2; expectations regarding
Vaxart’s ability to develop effective vaccines against new and
emerging variant strains; and Vaxart’s expectations with respect to
the effectiveness of its product candidates, including Vaxart’s
potential role in mitigating the impact of Covid-19. Vaxart may not
actually achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Vaxart makes, including
uncertainties inherent in research and development, including the
ability to meet anticipated clinical endpoints, commencement and/or
completion dates for clinical , regulatory submission dates,
regulatory approval dates and/or launch dates, as well as the
possibility of unfavorable new clinical data and further analyses
of existing clinical data; the risk that clinical trial data are
subject to differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from the clinical studies; decisions by
regulatory authorities impacting labeling, manufacturing processes,
and safety that could affect the availability or commercial
potential of any product candidate, including the possibility that
Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; that a Vaxart collaborator may
not attain development and commercial milestones; that Vaxart or
its partners may experience manufacturing issues and delays due to
events within, or outside of, Vaxart’s or its partners control,
including the recent outbreak of Covid-19; difficulties in
production, particularly in scaling up initial production,
including difficulties with production costs and yields, quality
control, including stability of the product candidate and quality
assurance testing, shortages of qualified personnel or key raw
materials, and compliance with strictly enforced federal, state,
and foreign regulations; that Vaxart may not be able to obtain,
maintain and enforce necessary patent and other intellectual
property protection; that Vaxart’s capital resources may be
inadequate; Vaxart’s ability to resolve pending legal matters;
Vaxart’s ability to obtain sufficient capital to fund its
operations on terms acceptable to Vaxart, if at all; the impact of
government healthcare proposals and policies; competitive factors;
and other risks described in the “Risk Factors” sections of
Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contacts
Brant BiehnVaxart, Inc.650 550 3500IR@vaxart.com |
Mark HerrVaxart, Inc.650 550 3500Mherr@vaxart.com |
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024